Appears to enhance weightloss and glucose effects when combined with GLP1, based on dualagonist data (such as tirzepatide). Glucagon receptor activation Increases energy expenditure and promotes fat oxidation when balanced properly with GLP1 and GIP. May help reduce liver fat and visceral (deep abdominal) fat, which are strongly linked to cardiometabolic risk. By combining these three pathways, retatrutide aims to reduce appetite, improve metabolic control, and increase calorie burning more strongly than current single or dualagonist drugs
The FLOW trial showed semaglutide reduced kidney disease progression by 24% in people with type 2 diabetes, with the investigators stating the kidney benefit was unrelated to weight changes
Individual results and risks vary and must be assessed by a physician
Here's how to operate within a Functional Medicine 2.0 framework where pharmacology and physiology work in synergy: Perform Baseline Comprehensive Testing Go beyond A1C and glucose
It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease
The table utilizes clinical evidence from trials measuring appetite scores and food consumption over a designated time frame
